secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2022-10-20T23:59:59+00:00
Accession:  0001867096-22-000117
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris reports positive Phase 1 data for SC levothyroxine (XP-8121); weekly dosing matches daily oral
--------------------------------------------------------------------------------

- Phase 1 study (n=60) shows proof-of-concept for once-weekly SC XP-8121 with steady-state exposure similar to daily oral Synthroid.
- Population PK model implies dose conversion factor of 4X: weekly 1200 μg SC equivalent to daily 300 μg PO levothyroxine.
- XP-8121 well tolerated at all doses (600, 1200, 1500 μg); safety profile comparable to Synthroid 600 μg PO.
- Company expects FDA End-of-Phase 1 meeting feedback by end of 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000117/0001867096-22-000117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000117/xers-20221020.htm
  HTML page:      https://secwatch.observer/filing/0001867096-22-000117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer